TMCnet News
TraceLink NEXUS 17 Attendees Cite Information Sharing as Largest Benefit Expected from End-to-End Visibility of Pharmaceutical Supply ChainNORTH READING, Massachusetts, June 29, 2017 /PRNewswire/ -- TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announces new industry findings from its annual conference, NEXUS 17. Interactive polling results indicated that the majority of pharmaceutical supply chain professionals (78 percent of attendees), believe that end-to-end visibility of pharmaceutical products in the supply chain is achievable within the next five years, with information sharing between trading partners cited as one of the most valuable business benefits. At NEXUS 17 in Barcelona earlier this month, TraceLink introduced its strategy for leveraging the industry's only digital supply chain network to facilitate a new era of real-time information sharing, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients. The first application unveiled within this road map, the Pharmacy Compliance and Digital Information Platform, enables any EU pharmacy to easily comply with verification and decommissioning requirements under the Falsified Medicines Directive (FMD), while simultaneously delivering a real-time dashboard for insights into pharmacy operations and enabling a direct communication channel from the pharmaceutical manufacturer to the pharmacy. As the premier venue for the convergence of the pharmaceutical supply chain, NEXUS 17 drew more than 200 pharmaceutical supply chain professionals and business leaders, representing over 120 unique companies from 21 different countries. The conference included educational content from 30 speakers, including esteemed keynote speaker, Dr. Bertalan Mesko – "The Medical Futurist" and experts from Sanofi, Santen, Recipharm, Tjoapack, MIT and the European Medicines Verification Organisation (EMVO). Attendees participated in live interactive polling throughout the two days, sharing their own insights and perspective on the topics covered in the keynotes, breakout sessions, and roundtable workshops. "here is tremendous value in connecting companies and trade partners together in an educational forum, allowing everyone to equally learn from collective wisdom. This year, NEXUS truly showcased the power of the network in the pharmaceutical supply chain – demonstrated through inspirational keynotes, dynamic breakout and roundtable discussions, and high attendee engagement during the networking sessions," said Shabbir Dahod, president and CEO, TraceLink. "As serialization deadlines fall into place, now is the time to leverage the foundation of an integrated network in order to enhance real-time communication and information exchange between all of the partners in the supply chain. From the very beginning, TraceLink has been architected with true interconnectedness, and by enabling the flow of serialization data between over 260,000 trade partners on our network, is the only provider that can deliver the next step of capabilities by taking information and moving it end-to-end across the supply chain." In addition to discussions around achieving valuable benefits beyond compliance, NEXUS 17 attendees also responded to questions about serialization preparation, challenges, and trade partner readiness, indicating the following:
To access the full polling data results from NEXUS 17, download the Serialization Snapshot: The Current State of Readiness. For those that missed NEXUS 17, photos and keynote slide presentations are available at www.nexus-tracelink.com. About TraceLink TraceLink is funded by Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital. |